Neuland Laboratories (NSE:NEULANDLAB) Owner Earnings per Share (TTM): 170.91 (As of Mar. 2026) — 263% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NEULANDLAB Neuland Laboratories Ltd NSE:NEULANDLAB
93 GF Score
Price ₹18,466.00
GF Value ₹16,128.05
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Neuland Laboratories Owner Earnings per Share (TTM)?

Neuland Laboratories NSE:NEULANDLAB -2.27% 93 Owner Earnings per Share (TTM) is 170.91 as of Mar. 2026, which is 263% above its 10-year median of 47.04. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 93/100 and a GF Value™ of ₹16,128.05 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 475 Drug Manufacturers companies, Neuland Laboratories ranks worse than 88% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Neuland Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2026 was ₹170.91. It's Price-to-Owner-Earnings ratio for today is 108.05.


The historical rank and industry rank for Neuland Laboratories's Owner Earnings per Share (TTM) or its related term are showing as below:

NSE:NEULANDLAB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.14   Med: 47.04   Max: 114.26
Current: 107.86


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Neuland Laboratories was 114.26. The lowest was 15.14. And the median was 47.04.


NSE:NEULANDLAB's Price-to-Owner-Earnings is ranked worse than
88% of 475 companies
in the Drug Manufacturers industry
Industry Median: 23.88 vs NSE:NEULANDLAB: 107.86

Neuland Laboratories's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was ₹165.76. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹283.70. It's PE Ratio (TTM) ratio for today is 65.09.

Neuland Laboratories's EPS without NRI for the three months ended in Mar. 2026 was ₹165.76. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹283.70. It's PE Ratio without NRI ratio for today is 65.09.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Neuland Laboratories Owner Earnings per Share (TTM) Related Terms


Neuland Laboratories Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for Neuland Laboratories's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuland Laboratories Owner Earnings per Share (TTM) Chart

Neuland Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.99 119.16 180.11 237.24 171.01

Neuland Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.24 0.00 0.00 0.00 171.01

NSE:NEULANDLAB vs ZTS, UTHR: Owner Earnings per Share (TTM) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories Price-to-Owner-Earnings vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Price-to-Owner-Earnings falls into.


NSE:NEULANDLAB
93GF Score
Neuland Laboratories Ltd NSE:NEULANDLAB
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuland Laboratories Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Neuland Laboratories's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income 3,640
Depreciation, Depletion and Amortization 917
Change In Deferred Tax 0
5Y Average of Maintenance Capital Expenditure 952
Change In Working Capital -1,414
Shares Outstanding (Diluted Average) 13

1. Start with "Net Income" from income statement. Neuland Laboratories's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,640 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Neuland Laboratories's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was ₹917 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Neuland Laboratories's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = ₹952 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Neuland Laboratories's 5-Year Average Maintenance Capital Expenditure = ₹952 Mil

5. "Change In Working Capital" is from cashflow statement. Neuland Laboratories's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-1,414 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Neuland Laboratories's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 12.830 Mil.

Neuland Laboratories's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 3639.984 +917.395+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-951.724+-1414.224)/12.830
=170.91

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=18466.00/170.91
=108.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of 170.91 mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Owner Earnings per Share (TTM) of 170.91 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Neuland Laboratories. This is 263% above median its historical median of 47.04. Over the past decade, Neuland Laboratories' Owner Earnings per Share (TTM) has ranged from 15.14 to 114.26. According to the industry distribution chart, Neuland Laboratories ranks #418 out of 475 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is Neuland Laboratories' Owner Earnings per Share (TTM) too high?
Neuland Laboratories' current Owner Earnings per Share (TTM) of 170.91 is 263% above median its 10-year median of 47.04. Over the past 10 years, this metric has ranged from a low of 15.14 to a high of 114.26. The Drug Manufacturers industry median Owner Earnings per Share (TTM) is 23.88. Neuland Laboratories' value of 170.91 is 615.7% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #418 out of 475 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Owner Earnings per Share (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #418 out of 475 companies for Owner Earnings per Share (TTM). This places Neuland Laboratories in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 23.88. Neuland Laboratories' value of 170.91 is 615.7% above this benchmark. Historically, Neuland Laboratories' own Owner Earnings per Share (TTM) has ranged from 15.14 to 114.26 over the past decade. While the company's 10-year median is 47.04 vs. the industry median of 23.88, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Drug Manufacturers company?
The median Owner Earnings per Share (TTM) among Drug Manufacturers companies is 23.88, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Owner Earnings per Share (TTM) of 170.91 is 615.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on Neuland Laboratories. For the Drug Manufacturers industry, the median Owner Earnings per Share (TTM) is 23.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Owner Earnings per Share (TTM) is 170.91, which is 263% above median its own 10-year median of 47.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,128.05, compared to a current price of ₹18,466.00 — trading 14.5% above its estimated fair value. The current Owner Earnings per Share (TTM) is 170.91, which is 263% above median its 10-year median of 47.04 and 615.7% above the Drug Manufacturers industry median of 23.88. Neuland Laboratories' overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Owner Earnings per Share (TTM) is 170.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued. The current stock price of ₹18,466.00 is trading 14.5% above its estimated GF Value™ of ₹16,128.05. GuruFocus considers Neuland Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:NEULANDLAB:

  • Owner Earnings per Share (TTM): 170.91 (263% above median its 10-year median of 47.04)
  • GF Value™: ₹16,128.05 vs. price of ₹18,466.00 (14.5% above fair value)
  • GF Score™: 93/100 with 1 warning sign
  • Industry Position: 615.7% above the Drug Manufacturers median (#418 of 475)

No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neuland Laboratories Business Description

Other Exchanges 524558:India
Address Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
93GF Score

Get the complete analysis for NSE:NEULANDLAB

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹18,466.00
Price
₹16,128.05
GF Value